2018-2023 Global Drugs for Vulvovaginal Candidiasis Consumption Market Report
Published On: August 2018
 
Report ID:310935
 
 
Pages: 131




In this report, Fior Markets covers the present scenario (with the base year being 2017) and the growth prospects of global Drugs for Vulvovaginal Candidiasis market for 2018-2023.

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.

The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.

Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.

Over the next five years, Fior Markets projects that Drugs for Vulvovaginal Candidiasis will register a 2.1% CAGR in terms of revenue, reach US$ 870 million by 2023, from US$ 770 million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Vulvovaginal Candidiasis market by product type, application, key manufacturers and key regions.

To calculate the market size, Fior Markets considers value and volume generated from the sales of the following segments:

Segmentation by product type:

Cream

Pessary

Other

Segmentation by application:

Hospital & Clinic

Pharmacy

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Spain

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

Bayer

Perrigo

J & J

Pfizer

Bristol-Myers Squibb

Effik

Teva

Sanofi

Cisen Pharmaceutical

Kingyork Group

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Drugs for Vulvovaginal Candidiasis consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.

To understand the structure of Drugs for Vulvovaginal Candidiasis market by identifying its various subsegments.

Focuses on the key global Drugs for Vulvovaginal Candidiasis manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Drugs for Vulvovaginal Candidiasis with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Drugs for Vulvovaginal Candidiasis submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

2018-2023 Global Drugs for Vulvovaginal Candidiasis Consumption Market Report

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Economic Indicators

1.6 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption 2013-2023

2.1.2 Drugs for Vulvovaginal Candidiasis Consumption CAGR by Region

2.2 Drugs for Vulvovaginal Candidiasis Segment by Type

2.2.1 Cream

2.2.2 Pessary

2.2.3 Other

2.3 Drugs for Vulvovaginal Candidiasis Consumption by Type

2.3.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Type (2013-2018)

2.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)

2.3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2013-2018)

2.4 Drugs for Vulvovaginal Candidiasis Segment by Application

2.4.1 Hospital & Clinic

2.4.2 Pharmacy

2.5 Drugs for Vulvovaginal Candidiasis Consumption by Application

2.5.1 Global Drugs for Vulvovaginal Candidiasis Consumption Market Share by Application (2013-2018)

2.5.2 Global Drugs for Vulvovaginal Candidiasis Value and Market Share by Application (2013-2018)

2.5.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Application (2013-2018)

3 Global Drugs for Vulvovaginal Candidiasis by Players

3.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players

3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Players (2016-2018)

3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Players (2016-2018)

3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players

3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Players (2016-2018)

3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Players (2016-2018)

3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Players

3.4 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Sales Area, Product Types by Players

3.4.1 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution and Sales Area by Players

3.4.2 Players Drugs for Vulvovaginal Candidiasis Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 Drugs for Vulvovaginal Candidiasis by Regions

4.1 Drugs for Vulvovaginal Candidiasis by Regions

4.1.1 Global Drugs for Vulvovaginal Candidiasis Consumption by Regions

4.1.2 Global Drugs for Vulvovaginal Candidiasis Value by Regions

4.2 Americas Drugs for Vulvovaginal Candidiasis Consumption Growth

4.3 APAC Drugs for Vulvovaginal Candidiasis Consumption Growth

4.4 Europe Drugs for Vulvovaginal Candidiasis Consumption Growth

4.5 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption Growth

5 Americas

5.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries

5.1.1 Americas Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)

5.1.2 Americas Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)

5.2 Americas Drugs for Vulvovaginal Candidiasis Consumption by Type

5.3 Americas Drugs for Vulvovaginal Candidiasis Consumption by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries

6.1.1 APAC Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)

6.1.2 APAC Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)

6.2 APAC Drugs for Vulvovaginal Candidiasis Consumption by Type

6.3 APAC Drugs for Vulvovaginal Candidiasis Consumption by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Countries

7 Europe

7.1 Europe Drugs for Vulvovaginal Candidiasis by Countries

7.1.1 Europe Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)

7.1.2 Europe Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)

7.2 Europe Drugs for Vulvovaginal Candidiasis Consumption by Type

7.3 Europe Drugs for Vulvovaginal Candidiasis Consumption by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Spain

7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis by Countries

8.1.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Countries (2013-2018)

8.1.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Value by Countries (2013-2018)

8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Type

8.3 Middle East & Africa Drugs for Vulvovaginal Candidiasis Consumption by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.2 Drugs for Vulvovaginal Candidiasis Distributors

10.3 Drugs for Vulvovaginal Candidiasis Customer

11 Global Drugs for Vulvovaginal Candidiasis Market Forecast

11.1 Global Drugs for Vulvovaginal Candidiasis Consumption Forecast (2018-2023)

11.2 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions

11.2.1 Global Drugs for Vulvovaginal Candidiasis Forecast by Regions (2018-2023)

11.2.2 Global Drugs for Vulvovaginal Candidiasis Value Forecast by Regions (2018-2023)

11.2.3 Americas Consumption Forecast

11.2.4 APAC Consumption Forecast

11.2.5 Europe Consumption Forecast

11.2.6 Middle East & Africa Consumption Forecast

11.3 Americas Forecast by Countries

11.3.1 United States Market Forecast

11.3.2 Canada Market Forecast

11.3.3 Mexico Market Forecast

11.3.4 Brazil Market Forecast

11.4 APAC Forecast by Countries

11.4.1 China Market Forecast

11.4.2 Japan Market Forecast

11.4.3 Korea Market Forecast

11.4.4 Southeast Asia Market Forecast

11.4.5 India Market Forecast

11.4.6 Australia Market Forecast

11.5 Europe Forecast by Countries

11.5.1 Germany Market Forecast

11.5.2 France Market Forecast

11.5.3 UK Market Forecast

11.5.4 Italy Market Forecast

11.5.5 Russia Market Forecast

11.5.6 Spain Market Forecast

11.6 Middle East & Africa Forecast by Countries

11.6.1 Egypt Market Forecast

11.6.2 South Africa Market Forecast

11.6.3 Israel Market Forecast

11.6.4 Turkey Market Forecast

11.6.5 GCC Countries Market Forecast

11.7 Global Drugs for Vulvovaginal Candidiasis Forecast by Type

11.8 Global Drugs for Vulvovaginal Candidiasis Forecast by Application

12 Key Players Analysis

12.1 Bayer

12.1.1 Company Details

12.1.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.1.4 Main Business Overview

12.1.5 Bayer News

12.2 Perrigo

12.2.1 Company Details

12.2.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.2.4 Main Business Overview

12.2.5 Perrigo News

12.3 J & J

12.3.1 Company Details

12.3.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.3.4 Main Business Overview

12.3.5 J & J News

12.4 Pfizer

12.4.1 Company Details

12.4.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.4.4 Main Business Overview

12.4.5 Pfizer News

12.5 Bristol-Myers Squibb

12.5.1 Company Details

12.5.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.5.4 Main Business Overview

12.5.5 Bristol-Myers Squibb News

12.6 Effik

12.6.1 Company Details

12.6.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.6.4 Main Business Overview

12.6.5 Effik News

12.7 Teva

12.7.1 Company Details

12.7.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.7.4 Main Business Overview

12.7.5 Teva News

12.8 Sanofi

12.8.1 Company Details

12.8.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.8.4 Main Business Overview

12.8.5 Sanofi News

12.9 Cisen Pharmaceutical

12.9.1 Company Details

12.9.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.9.4 Main Business Overview

12.9.5 Cisen Pharmaceutical News

12.10 Kingyork Group

12.10.1 Company Details

12.10.2 Drugs for Vulvovaginal Candidiasis Product Offered

12.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2016-2018)

12.10.4 Main Business Overview

12.10.5 Kingyork Group News

13 Research Findings and Conclusion




Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \


Copyright © 2019 Fior Market Research LLP, All Rights Reserved.